Celsion (CLSN) Says ThermoDox Missed Primary Endpoint in Phase III HEAT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Roth Capital Downgrades Celsion Corp (CLSN) to Neutral
January 31, 2013 2:57 PM ESTEarlier, Roth Capital downgraded Celsion Corp (NASDAQ: CLSN) from Buy to Neutral with a price target of $1.70 (from $10.00) following today's trial failure.
For an analyst ratings summary and ratings history on Celsion Corp click here. For more ratings news on Celsion Corp click here.
Shares of Celsion are down 81% to $1.52.... More
Celsion (CLSN) will resume trading at 7:30AM after Trial Failure
January 31, 2013 7:27 AM ESTCelsion Corporation (NASDAQ: CLSN) will resume trading at 7:30AM ThermoDox Missed Primary Endpoint in Phase III HEAT... More
Celsion (CLSN) to Hold Phase III HEAT Call on Jan. 31; Receives Priority Trial Designation
January 30, 2013 4:15 PM ESTCelsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Thursday, January 31, 2013 to present the top-line results from its pivotal Phase III HEAT Study with ThermoDox® in combination... More
Celsion (CLSN) trading halted with news pending
January 30, 2013 4:03 PM ESTCelsion Corporation (NASDAQ: CLSN) trading halted with news pending.... More
